blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1615658

EP1615658 - INHIBITION OF TUMOR CELL PROLIFERATION BY FOXM1B INHIBITORS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  17.04.2015
Database last updated on 30.10.2024
Most recent event   Tooltip17.04.2015Application deemed to be withdrawnpublished on 20.05.2015  [2015/21]
Applicant(s)For all designated states
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
352 Henry Administration Building
506 South Wright Street
Urbana, IL 61801 / US
[N/P]
Former [2006/03]For all designated states
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
352 Henry Administration Building, 506 South Wright Street
Urbana, IL 61801 / US
Inventor(s)01 / COSTA, Robert, H.
946 Wisconsin Avenue
Oak Park, IL 60304 / US
02 / RAYCHAUDHURI, Pradip
144 Westley Avenue
Oak Park, IL 60302 / US
03 / WANG, Xinhe
1764 Merriweather Drive
Upper Arlington, OH 43221 / US
04 / KALINICHENKO, Vladimir
415 Traube Avenue
Clarendon Hills, IL 60514 / US
05 / MAJOR, Michael
3N482 Vachel Lindsay Street
Saint Charles, IL 60175 / US
06 / WANG, I-Ching
1933 West Polk Street, Apt. 1403B
Chicago, IL 60612 / US
 [2007/13]
Former [2006/03]01 / COSTA, Robert, H.
946 Wisconsin Avenue
Oak Park, IL 60304 / US
02 / RAYCHAUDHURI, Pradip
144 Westley Avenue
Oak Park, IL 60302 / US
03 / WANG, Xinhe
1764 Merriweather Drive
Upper Arlington, OH 43221 / US
04 / KALINICHENKO, Vladimir
415 Traube Avenue
Clarendon Hills, IL 60514 / US
05 / MAJOR, Michael
23 N. Racine Avenue, Unit 406
Chicago, IL 60607 / US
06 / WANG, I-Ching
1933 West Polk Street, Apt. 1403B
Chicago, IL 60612 / US
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstrasse 4
80802 München / DE
[N/P]
Former [2006/03]Grünecker, Kinkeldey, Stockmair & Schwanhäusser Anwaltssozietät
Maximilianstrasse 58
80538 München / DE
Application number, filing date04749478.625.03.2004
[2006/03]
WO2004US09454
Priority number, dateUS20030457257P25.03.2003         Original published format: US 457257 P
US20030474075P29.05.2003         Original published format: US 474075 P
US20030513809P23.10.2003         Original published format: US 513809 P
US20040540691P30.01.2004         Original published format: US 540691 P
US20040549211P02.03.2004         Original published format: US 549211 P
[2006/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2004100977
Date:25.11.2004
Language:EN
[2004/48]
Type: A1 Application with search report 
No.:EP1615658
Date:18.01.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 25.11.2004 takes the place of the publication of the European patent application.
[2006/03]
Search report(s)International search report - published on:EP25.11.2004
ClassificationIPC:A61K38/17, A61K31/277, A61K31/55, C12N15/11, G01N33/50, A61P35/00
[2006/03]
CPC:
A01K67/0276 (EP,US); A61K31/00 (EP,US); A61K31/277 (EP,US);
A61K31/55 (EP,US); A61K38/1709 (EP,US); A61P35/00 (EP);
C12N15/113 (EP,US); G01N33/57496 (EP,US); A01K2217/075 (EP,US);
A01K2227/105 (EP,US); A01K2267/0337 (EP,US); A61K48/00 (EP,US);
C12N2310/111 (EP,US); C12N2800/30 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/03]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:HEMMUNG DER TUMORZELLPROLIFERATION MITTELS FOXM1B-HEMMER[2006/03]
English:INHIBITION OF TUMOR CELL PROLIFERATION BY FOXM1B INHIBITORS[2006/03]
French:PROCEDE D'INHIBITION DE PROLIFERATION DE CELLULES TUMORALES[2006/03]
Entry into regional phase25.10.2005National basic fee paid 
25.10.2005Designation fee(s) paid 
25.10.2005Examination fee paid 
Examination procedure17.09.2004Request for preliminary examination filed
International Preliminary Examining Authority: EP
25.10.2005Examination requested  [2006/03]
15.12.2005Amendment by applicant (claims and/or description)
15.07.2010Despatch of a communication from the examining division (Time limit: M08)
25.03.2011Reply to a communication from the examining division
11.03.2013Despatch of a communication from the examining division (Time limit: M06)
23.09.2013Reply to a communication from the examining division
26.05.2014Despatch of a communication from the examining division (Time limit: M06)
06.12.2014Application deemed to be withdrawn, date of legal effect  [2015/21]
14.01.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2015/21]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.07.2010
Fees paidRenewal fee
29.03.2006Renewal fee patent year 03
28.03.2007Renewal fee patent year 04
27.03.2008Renewal fee patent year 05
26.03.2009Renewal fee patent year 06
25.03.2010Renewal fee patent year 07
28.03.2011Renewal fee patent year 08
26.03.2012Renewal fee patent year 09
27.03.2013Renewal fee patent year 10
27.03.2014Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XY]US6172194  (SHERR CHARLES J [US], et al) [X] 1-3,7-10,13-15,19,20,24-27,29-31 * column 5, lines 9-43 * [Y] 11,17,18;
 [X]WO0160374  (CENTRE NAT RECH SCIENT [FR], et al) [X] 1-3,7-10,12-15,19,20,24-31 * page 2, lines 3-19 * * page 9, lines 23-26 *;
 [X]WO0226236  (UNIV VIRGINIA COMMONWEALTH [US], et al) [X] 1-3,7-10,13-15,19,20,24-27,29-31 * claims 1,4-7 *;
 [X]US2002156023  (WALLING JACQUELINE MARY [GB], et al) [X] 1-10,13,15,19-27,29-31 * claims 1,5,8 *;
 [X]US2002155988  (O'HARE PETER FRANCIS JOSEPH [GB], et al) [X] 1-3,7-10,12-15,19,20,24-31 * paragraph [0038]; claims 1,2,5 *;
 [X]WO02083140  (MERCK & CO INC [US], et al) [X] 1-3,7-10,13-15,19,20,24-27,29-31 * page 1, lines 5-9 *;
 [DA]WO02092013  (UNIV ILLINOIS [US], et al);
 [XY]US2002193325  (DEPINHO RONALD A [US]) [X] 1-3,7-10,13-15,19,20,24-27,29-31 * claim - * [Y] 11,17,18;
 [X]  - SUPRIATNO HARADA K ET AL, "Overexpression of p27 induces growth arrest and apoptosis in an oral cancer cell line", ORAL ONCOLOGY, ELSEVIER SCIENCE, OXFORD, GB, (200210), vol. 38, no. 7, ISSN 1368-8375, pages 730 - 736, XP004375954 [X] 1-3,7-10,12-15,19,20,24-31 * page 733, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/S1368-8375(02)00011-8
 [AD]  - TEH MUY-TECK ET AL, "FOXM1 is a downstream target of Gli1 in basal cell carcinomas", CANCER RESEARCH, (20020815), vol. 62, no. 16, ISSN 0008-5472, pages 4773 - 4780, XP002299512
Examination   - WENDER P A ET AL, The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, PAGE(S) 13003 - 13008, (20001121), ISSN 0027-8424, XP002347555

DOI:   http://dx.doi.org/10.1073/pnas.97.24.13003
    - BECKER-HAPAK M ET AL, "TAT-MEDIATED PROTEIN TRANSDUCTION INTO MAMMALIAN CELLS", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, (20010701), vol. 24, no. 3, doi:10.1006/METH.2001.1186, ISSN 1046-2023, pages 247 - 256, XP001085166

DOI:   http://dx.doi.org/10.1006/meth.2001.1186
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.